An announcement from Agenus (AGEN) is now available.
Dr. Jennifer Buell, with over 27 years in the biopharmaceutical industry, has been appointed to the Board of Directors of Agenus Inc. as of June 11, 2024. Her extensive background includes various leadership roles, most notably as President and CEO of MiNK Therapeutics and previous positions within Agenus, including COO and President. Dr. Buell’s expertise spans from advancing clinical developments to commercializing discovery candidates. She also holds a Ph.D. in Cellular, Biochemical, and Molecular Biochemistry from Tufts University. Her appointment is a strategic move for Agenus, leveraging her rich experience and knowledge in the sector.
For an in-depth examination of AGEN stock, go to TipRanks’ Stock Analysis page.
